USP22 and hepatocellular carcinoma: USP22 expression, which was classified as high or low based on the ROC-derived cutoff, was mainly found to be higher in patients with more advanced tumor stages (stages III and IV) and higher tumor grades (grades 3-4), indicating that USP22 might be involved in HCC progression.